Stock Events

Stock Events

Editas Medicine 

$3.23
282
+$0.15+4.87% Friday 20:00
-$0.03-0.93%Friday 23:30After hours

Statistics

Day High
3.23
Day Low
3.04
52W High
4.54
52W Low
1.66
Volume
1,387,420
Avg. Volume
2,349,536
Mkt Cap
496.06M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

9NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.92
-0.66
-0.41
-0.15
Expected EPS
-0.190272
Actual EPS
N/A

Financials

-395.01%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
40.52MRevenue
-160.06MNet Income

Analyst Ratings

6.00Average Price Target
The highest estimate is 8.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EDIT. It's not an investment recommendation.
CRISPR Therapeutics
63
CRSP
Tesla
53
TSLA
Amazon
52
AMZN
Microsoft
51
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.58B
CRISPR Therapeutics is directly competing in the CRISPR/Cas9 gene-editing space, focusing on developing transformative gene-based medicines for serious diseases.
Intellia Therapeutics
NTLA
Mkt Cap1.8B
Intellia Therapeutics is a leading competitor in the development of in vivo gene editing treatments using CRISPR/Cas9 technology, similar to Editas' approach.
Beam Therapeutics
BEAM
Mkt Cap3.03B
Beam Therapeutics uses base editing, a newer form of gene editing technology that competes with CRISPR/Cas9 methods employed by Editas for precise and reduced-risk gene editing.
Alnylam Pharmaceuticals
ALNY
Mkt Cap31.73B
Alnylam Pharmaceuticals competes in the RNAi therapeutic space, offering a different approach to gene therapy that could rival Editas' gene editing technologies.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals collaborates with CRISPR Therapeutics on gene editing therapies, indirectly competing with Editas through their joint development efforts in the CRISPR/Cas9 space.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other genetic disorder treatments, competing with Editas in the broader market for genetic disease therapies.
PTC Therapeutics
PTCT
Mkt Cap5.85B
PTC Therapeutics operates in the genetic disorder space, offering treatments that could compete with gene editing therapies developed by Editas.
Ionis Pharmaceuticals
IONS
Mkt Cap10.15B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery and development, presenting a competitive alternative to Editas' gene editing approach.

About

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.
Show more...
CEO
Gilmore O'Neill
Employees
87
Country
United States
ISIN
US28106W1036
WKN
000A2AC4K

Listings

LSE
GB
0IFK.LSE
STU
DE
8EM.STU
MU
DE
8EM.MU
XNAS
US
EDIT

0 Comments

Share your thoughts

FAQ

What is Editas Medicine stock price today?▼
The current price of EDIT is $3.23 USD — it has increased by +4.87% in the past 24 hours. Watch Editas Medicine stock price performance more closely on the chart.
What is Editas Medicine stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Editas Medicine stocks are traded under the ticker EDIT.
Is Editas Medicine stock price growing?▼
EDIT stock has risen by +2.22% compared to the previous week, the month change is a +17.45% rise, over the last year Editas Medicine has showed a +17.03% increase.
What is Editas Medicine market cap?▼
Today Editas Medicine has the market capitalization of 496.06M
When is the next Editas Medicine earnings date?▼
Editas Medicine is going to release the next earnings report on November 09, 2026.
What were Editas Medicine earnings last quarter?▼
EDIT earnings for the last quarter are -0.15 USD per share, whereas the estimation was -0.27 USD resulting in a +44.55% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Editas Medicine revenue for the last year?▼
Editas Medicine revenue for the last year amounts to 40.52M USD.
What is Editas Medicine net income for the last year?▼
EDIT net income for the last year is -160.06M USD.
How many employees does Editas Medicine have?▼
As of September 05, 2026, the company has 87 employees.
In which sector is Editas Medicine located?▼
Editas Medicine operates in the Health & Wellness sector.
When did Editas Medicine complete a stock split?▼
Editas Medicine has not had any recent stock splits.
Where is Editas Medicine headquartered?▼
Editas Medicine is headquartered in CAMBRIDGE, United States.